Introduction
The achievement of temporary remission in a variety of human cancers (1) (2) (3) clearly points to the potential of lymphokineactivated killer (LAK)1 cell therapy. However, LAK cell ther- 1 . Abbreviations used in this paper: AML, acute myelogenous leukemia; ABMT, autologous bone marrow transplantation; BM, bone marrow; CsA, Cyclosporin A; E/T ratio, effector/target ratio; i.p., intraperitoneal; LAK, lymphokine-activated killer; MRD, minimal residual disease; PB, peripheral blood; rh, recombinant human; SCID, severe combined immunodeficient. apy has had little success against established metastatic disease (2) . Two major problems affect the efficiency of adoptively transferred LAK cells: one is the inadequate tumoricidal activity of these MHC nonrestricted polyclonal killer cells; the second is the unavailability of sufficient numbers of activated effectors that retain both cytotoxic and tumor-targeting capabilities. The high doses of recombinant human (rh) IL-2 administered to the patients to circumvent these limitations have been associated with severe side effects (2, (4) (5) (6) . Several alternate approaches have been proposed to improve cancer therapy, including the use of antigen-specific tumor-infiltrating cytotoxic lymphocytes (7, 8) or of LAK cells linked with antibodies to tumor cell surface antigens (9, 10) , and genetic engineering of tumor cells with cytokine genes (such as IL-2, TNF, IFN-y, IL-4, IL-6, and IL-7), to promote enhanced anti-tumor immunity (11) (12) (13) (14) (15) .
Within hematologic malignancies, therapy with LAK cells and IL-2 has induced some clinical responses in patients with advanced malignant lymphoma or acute myelogenous leukemia (AML) (16) . It is postulated that administration of LAK cells with IL-2 might prevent or delay relapses if used as consolidative immunotherapy against the minimal residual disease (MRD) which exists after autologous bone marrow transplantation (ABMT). Although IL-2-responsive LAK precursor cells are in the circulation as early as 3 wk after ABMT, full LAK activity is recovered only 70-80 d after the transplant. The feasibility of generating and administering autologous LAK cells and IL-2 after ABMT in patients with high risk of relapse is now under investigation (16) . However, this therapeutic modality might have practical limitations in many patients with AML or acute lymphoblastic leukemia due to the scarcity of cytotoxic cells in their blood and to the often rapid disease progression.
We have developed a new experimental approach to adoptive immunotherapy that overcomes the inadequacy of autologous LAK cells and the severe side effects of rh IL-2 in vivo. This approach uses a lethally irradiated clonal human T cell line (TALL-104), which is endowed with potent MHC nonrestricted cytotoxic activity directed exclusively against tumor cells (17) (18) (19) . The TALL-104 cell line, originally derived from an infant with acute T-lymphoblastic leukemia (17) , has phenotypic markers typical of cytotoxic T cells (CD2', CD3/TCRaJ3 , CD4-/CD8+, CD7+, CD56', CD16-) and is maintained in continuous culture in the presence of rh IL-2. Its cytotoxicity can be supported independently by IL-2 or IL-12 and the two cytokines trigger this function in an additive fashion (20) . The ability of this cell line to engraft severe combined immunodeficient (SCID) mice (21 ) offered to us the opportunity to investigate its anti-tumor effects in an in vivo setting of human malignancies that can be implanted in these animals, including lymphoid and myeloid leukemias (21) (22) (23) . The SCID/U937 model was chosen in the present study because this human myelomonocytic leukemia cell line (a) is highly sensitive to LAK cell lysis, and (b) grows aggressively in SCID mice induc-ing fatal leukemia in a short time period (22) . Our findings demonstrate that in appropriate experimental conditions, TALL-104 cells can reverse the aggressive growth of U937 cells in SCID mouse tissues, leading to complete abrogation of AML. Moreover, multiple transfers of lethally irradiated TALL-104 cells co-injected with rh IL-2 at the time of tumor challenge completely eradicated the presence of U937 cells in the murine host. These findings suggest the possible use of cytokine-activated, nonproliferating, allogeneic effectors in adoptive transfer therapy.
Methods
Cell lines. The following human tumor cell lines were cultured at 370C in 5% CO2 in RPMI 1640 medium supplemented with 10% heat-inactivated FBS, glutamine, and antibiotics: U937 (myelomonocytic leukemia), Raji (B cell lymphoma), U-87MG (glioblastoma), 2774 (ovarian carcinoma), Hs568T (breast carcinoma), 5673 (bladder carcinoma), A549 (lung carcinoma), and CHP-100 (neuroblastoma). All cell lines were free of mycoplasma contamination upon repeated testing. TALL-104 cells were maintained in Iscove's modified Dulbecco's medium supplemented with 10% FBS and rh IL-2 (100 U/ml) (sp act 1 X 107 U/mg), a generous gift from Dr. Maurice Gately (Hoffman-La Roche, Nutley, NJ).
Tagging of U937 cells with a neomycin-resistance gene. The N2A double copy retroviral vector, containing the neomycin-resistance gene and the human IL-2 cDNA driven by the thymidine kinase promoter (24, 25) was obtained from Drs. E. Gilboa and Gansbacher (Memorial Sloan-Kettering Cancer Center, New York, NY) and used to infect U937 cells by lipofection according to published methods (26) . G-418 (genetycin, I mg/mi)-resistant U937 clones were subcloned by limiting dilution.
Mice. CB17 SCID mice, originally obtained from Dr. M. Bosma (Fox Chase Cancer Center, Philadelphia, PA), were bred and maintained in The Wistar Institute's animal facility. 6-wk-old IgM nonproducer SCID mice were immunosuppressed by intraperitoneal (i.p.) injection of etoposide (VP-16, 30 mg/kg), 4 d before implantation of U937 cells. Organs were minced through metal grids followed by FicollHypaque gradients to remove dead cells and erythrocytes (21) (22) (23) . Bone marrow (BM) samples from the femoral bones and peripheral blood (PB) drawn from the eye were stained with May-Grunwald Giemsa (21) (22) (23) (17) (18) (19) (20) .
Detection of residual U937 cells by PCR. PCR amplification of the neomycin-resistance gene present in U937 cells (see above) was done using two neomycin-specific primers which were synthesized in the DNA synthesis facility of the University of Pennsylvania (Philadelphia, PA). The sequence amplified by these primers is of 501 bp. A 32p_ labeled oligonucleotide probe recognizing 20 nucleotides in the middle of the amplified sequence was used for Southern blot hybridization to demonstrate the specificity of the PCR products (22) . DNAs were visualized with ethidium bromide after electrophoresis in 2% agarose gels, lx TAE buffer. Hybridization was carried out overnight at 50°C in 5x SSC, 1% SDS at room temperature for 30 min, and 2x SSC, 1% SDS for 30 min at 56°C (4°C less than the melting point of the oligo probe). The sensitivity of our PCR method using neomycin-specific primers allows us to detect one positive cell out of 2 x 105 cells.
PCR identification of human cells in the murine host. The presence of human cells (either effectors or targets) in SCID mouse tissues was evaluated by PCR analysis using two primers specific for human ALU-DNA sequences (27) . An 
Results
Tumoricidal activity of TALL-104 cells in vitro. Short-term effects of y-irradiation. TALL-104 cells display potent cytotoxic activity directed exclusively against tumor targets and do not lyse normal cells. Fig. I shows a representative 4-h 5"Cr-release assay in which cultured leukemic cell lines (Raji, U937), cell lines originated from solid tumors (the bladder carcinoma 5673, the glioblastoma multiform U-87 MG, and the ovarian carcinoma 2774), and uncultured cells freshly isolated from leukemic BM samples (an AML/FAB-M5 and a T-ALL), were efficiently lysed by TALL-104 cells, whereas the BM from three healthy donors (BM1, BM2, and BM3) were not affected at all. As detailed in a separate manuscript (Cesano, A., S. Visonneau, L. Cioe, S. C. Clark, and D. Santoli, manuscript submitted for publication), y-irradiation (4,000 rads, provided by a cesium source) blocks TALL-104 cell proliferation completely (3H-TdR incorporation is totally inhibited within 4 h) without significantly altering their killer function. Fig. 2 shows an experiment in which IL-2-activated TALL-104 cells were y irradiated and immediately tested for cytotoxicity in a 4-h 5"Cr-release assay: all types of human tumor targets tested (U937, U-87 MG, 2774, the lung carcinoma A549, breast cancer Hs568T, and neuroblastoma CHP-100) were killed as efficiently by the irradiated killers as by the nonirradiated counterpart at all effector/target (E/T) ratios tested. Long-term effects of y-irradiation on TALL-104 cell killing in response to rh IL-2 and rh IL-12. To compare the long-term cytotoxic responses of irradiated and nonirradiated TALL-104 cells to the same doses of IL-2 and IL-12, the U937 clone tagged with the neomycin-resistance gene was used as target, and PCR analysis using neomycin-specific primers was performed after a 5-d incubation. Fig. 3 shows that when nonirradiated TALL-104 cells were used, activation with rh IL-2 (100 U/ml) or rh IL-12 (10 ng/ml) (CHO cell derived, sp act 5. severe anemia. U937 cells were always detectable in the ascites, PB, BM, and spleen of these mice at death. Animals receiving 107 U937 cells were used to investigate the in vivo anti-tumor effects of TALL-104 cells; the cytotoxic activity of these effectors was optimized by priming the cells with 100 U/ml rh IL-2 for 18 h before in vivo transfer. Treatment was done at different times after injection of the AML target, and the survival of the mice was detennined for a span of several months, as indicated in Fig. 7 . Survivors, showing no symptoms after a 6-mo observation period, were sacrificed and the presence of human cells (both effectors and targets) in the BM was evaluated by PCR analysis using primers specific for human ALU-DNA sequences (27) . The most remarkable finding in the experiments presented in Fig. 7 (Fig. 6 b) , two developed AML and died 3 mo later, and two remained clinically and morphologically free of disease for at least 6 mo (Fig. 7) . PCR amplification of human ALU-DNA sequences provided molecular evidence for the persistence of residual cells in the BM of the survivors. Whether these cells represented TALL-104 effectors or U937 targets could not be determined in this set of experiments. Importantly, complete abrogation of AML, as monitored both clinically and by PCR analysis, was achieved by repeated injection of the effector cells on d 0, 3, and 6 (Fig. 7) . TALL-104 cells were injected at the same time as U937 cells on d 0 (i.e., without any delay) but on the opposite flank. PCR amplification of human ALU-DNA sequences in the BM of these mice, electively sacrificed 6 mo from treatment, demonstrated that both types of leukemic populations, the myeloid target and the lymphoid effector, were eliminated from the mouse tissues. The possibility that, upon effective interaction with the U937 target, the TALL-104 cells might have become anergic and died is consistent with the notion that, upon lysis of sensitive targets, cytotoxic cells enter an anergic phase followed by apoptotic death (28) . Another interesting observation from the experiments shown in Fig. 7 is that administration of low doses of rh IL-12 ( (Fig. 6, d and e) suggests that the anti-tumor effects in vivo occurred by cytocidal mechanisms similar to those observed in vitro. Anti-leukemic effects of y-irradiated TALL-104 cells in the SCID/U937 model. Based on the observations that lethally irradiated TALL-104 cells express tumoricidal activity in vitro (Fig. 2) and are able to circulate in SCID mouse tissues (Fig.  4) , experiments were performed to determine the extent to which irradiated TALL-104 cells display anti-tumor effects in the SCID/U937 model. To have an objective way for detection of MRD in the treated mice, the U937 clone tagged with the neomycin-resistance gene was used in these experiments. In addition to being killed by TALL-104 cells in vitro to the same extent as the unmodified U937 cell line, the neomycintransfected clone displayed exactly the same tumorigenic properties in SCID mice as the parental cells (data not shown). Moreover, the survival of SCID mice engrafted i.p. with the transfected U937 cells (Fig. 8 ) was similar to that observed with the unmodified cell line (Fig. 5) : animals injected i.p. with 107 neomycin-tagged cells died by d 12 and those injected with 3 x 105 cells died by d 56 (Fig. 8) . Fig. 9 (A and B) show the survival curve and PCR data, respectively, from an experiment in which SCID mice were challenged with transfected U937 cells and treated, or not, with the irradiated TALL-104 cells. The effectors were transferred on alternate days (2 x 107, i.p.), starting from the day of U937 cell challenge: as also indicated in the experiment shown in Fig. 7 (Fig. 9 B) . PCR analysis using neomycin-specific primers confirmed the presence of residual U937 cells in the same samples (Fig. 9 B) . By contrast, administration of rh IL-2 to TALL-104 cell-treated mice resulted in the total disappearance of molecularly detectable leukemic cells, using either type of primers (Fig. 9 B) (32) (33) (34) (35) have clearly shown that in a syngeneic BMT setting followed by IL-2 therapy, murine BM cells pre-activated with IL-2 in vitro are (1 gg/day) able to induce graft-versus-leukemia effects without inducing graft-versus-host disease. Maximum anti-leukemic effects were seen in the early posttransplant period possibly because of MRD during this time (35) . These findings might have important clinical implications in future ABMT settings for eradication of MRD by BM-activated killers (34) . The present investigation, performed in humanized SCID mice, demonstrates that a killer T cell clone, rendered immortal by culture in rh IL-2 (17), was able to antagonize efficiently the in vivo growth of the leukemic cell line U937, resulting in complete eradication of AML. TALL-104 cells kill hematopoietic and nonhematopoietic tumors (both cultured and freshly isolated) 5-20 times more efficiently than IL-2-expanded PBL from healthy donors (conventional LAK cells), yet are unable to recognize and kill cells from normal tissues, such as melanocytes, PBL, and BM cells, both in short-term 5'Cr-release assays and in long-term (14 d) clonogenic assays (18) (19) (20) . The extremely low numbers of TALL-104 cells required to kill tumor targets in vitro document the higher potency and recycling capability of this T cell clone as compared to heterogeneous LAK cell populations, and may partly explain the finding that lethal irradiation, while blocking cell proliferation and decreasing cell viability, does not affect significantly the tumoricidal activity of TALL-104 cells while abolishing that of LAK cells (Cesano, A., S. Visonneau, L. Cioe, S. C. Clark, and D. Santoli, manuscript submitted for publication).
The SCID/U937 model (22) was chosen in this study because of the extreme aggressiveness of U937 cells in SCID mouse tissues which permits the evaluation of therapeutic efficacy in a relatively short period of time. The encouraging data obtained in this model are now being extended to demonstrate the efficacy of adoptively transferred TALL-104 cells against fresh (uncultured) acute leukemias that are engraftable in SCID mice. These studies might demonstrate a differential sensitivity of various leukemia subsets (pre-B ALL, T-ALL, and AML of different FAB classification) to TALL-104 cell killing both in vitro and in vivo.
The possible enhancing effect of rh L-12 on tumor efficacy in vivo was investigated in the present study based on the ability of this cytokine to support TALL-104 cell cytotoxicity in vitro independently of IL-2 (20) , and because of its described immunomodulatory properties in defense against tumors (36, 37) . The finding that a single transfer of TALL-104 cells in conjunction with low doses of rh IL-12 (1 tzg/d) doubled the survival of the mice, as compared to mice receiving TALL-104 cells alone (Fig. 7) , suggests the ability of rh IL-12 to potentiate the tumoricidal activity of this cell line in vivo, in analogy with our in vitro observations (20) . To our knowledge, these data provide the first evidence that human IL-12 can enhance the anti-tumor effects of adoptively transferred CD3 +CD8 + cytotoxic cells in an in vivo situation. On the other hand, the finding that rh IL-12, at the same low dose, did not enhance the antitumor activity of y-irradiated TALL-104 cells, as detected both clinically and by PCR (Fig. 9) , indicates that, in this situation, the response to 1L-12 was inadequate or short lasting, and that higher doses of this cytokine might have to be used to potentiate the killer activity of y-irradiated TALL-104 cells in vivo. Indeed, the in vitro findings (Fig. 3) that the irradiated killers become totally unresponsive to rh IL-12 and less responsive to rh 1L-2 support the in vivo data in Fig. 9 . Experiments are under way to establish the doses of either cytokine that would elicit optimal cytotoxic responses in vitro and highly effective antitumor activity in vivo in the irradiated cells.
Multiple transfers of TALL-104 cells starting at the time of tumor challenge (i.e., when the tumor load was low) resulted in complete abrogation of AML, as seen both clinically and by PCR, regardless of whether adoptive therapy was done with the nonirradiated or the irradiated effectors (Figs. 7 and 9 ). In the latter case, co-injection of low doses of IL-2 was necessary to obtain total cure. Most notably, when TALL-104 cells were administered 3 d after tumor challenge (when the leukemic spread of U937 cells was advanced) (Fig. 7) , 50% of the mice showed a significantly longer survival as compared to untreated mice; based on the data in Fig. 5 , one can conclude that the tumor load in these animals was significantly reduced upon TALL-104 cell treatment. Remarkably, the remaining 50% of the mice remained clinically well for at least 6 mo. The presence of human ALU-DNA sequences in the BM of these animals at the time they were sacrificed suggests that they harbored residual leukemia. Although we could not rule out the presence of TALL-104 cells in these BM samples, the fact that the group of animals treated at the time of tumor challenge was PCR negative for human ALU-DNA sequences (Fig. 7) , suggests that, upon interaction with and killing of the U937 target, the effectors might have become anergic and died. This would be consistent with reported observations on the fate of killer cells after exposure to sensitive targets (28 (Figs. 7 and 9 ). In consideration that IL-2 and IL-12 induce high levels of IFN-y and TNF-a production by TALL-104 cells (20) , we looked at the direct effects of these cytokines on U937 cells in vitro and found that these cells were insensitive to growth inhibition by rh IFN-y and TNF-a at doses as high as 500 U/ml (data not shown). The inability of neutralizing antibodies to IFN-y and TNF-a to affect U937 cell killing by TALL-104 cells in vitro (not shown) is additional evidence against a role of these cytokines in the anti-leukemic effects observed in vivo. That the reversal of AML was a direct result of U937 cell killing by TALL-104 cells is also suggested by the finding that in a group of SCID-U937 mice injected with the noncytotoxic T cell line TALL-106 (17) , rather than with TALL-104 cells, U937 cell growth was not arrested at all and the animals died of AML at the same time as the control mice (not shown).
Overall, the in vivo experiments shown in this report demonstrate that: (a) nonproliferating TALL-104 cells co-injected with low doses of 11L-2 could effectively attack and completely eliminate U937 cells when present at E/T ratios 2 1:1; and (b) even when TALL-104 cell treatment was initiated during an advanced disease stage, at extremely low E/T ratio conditions, TALL-104 cells could still significantly prolong the survival of the mice and drastically reduce the tumor load. These observations point out possible approaches to AML treatment using TALL-104 cells at optimal E/T ratio conditions. Most notably, the observation that, in situations mimicking MRD, y-irradiated TALL-104 cells were In conclusion, this study indicates that more effective adoptive transfer protocols against cancer can be designed in the future using HLA-mismatched killers co-injected with nontoxic doses of appropriate cytokines and immunosuppressive drugs.
